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800Alloreactivity Across HLA Barriers Is Mediated by Both
Na€ıve and Antigen-Experienced T Cells
J. Joseph Melenhorst,1 Phillip Scheinberg,1,4 Ann Williams,2
David R. Ambrozak,3 Keyvan Keyvanfar,1 Melody Smith,1 J. Philip McCoy, Jr.,2
Nancy F. Hensel,1 Daniel C. Douek,4 A. John Barrett1T cell responses to allogeneic targets arise predominantly from the na€ıve pool. However, in humans, the risk of
graft-versus-host disease is increased if the donor has circulating T cells recognizing multiple persistent DNA
viruses, suggesting that memory T cells also contribute to the alloresponse. To examine HLA alloreactivity,
we used flow cytometry–based proliferation and cytokine production assays. We identified the clonal identity
of virus-specific T cells cross-reacting with HLA-disparate targets by sequencing the T cell receptor b chains in
virus-specificT cell lines restimulatedwith cognate andHLA-disparate targets and sorting these chains according
to cytokine response.We confirmed that na€ıve T cells from cord blood and adult individuals responded toHLA-
mismatched target cells. In addition, in adults, we identified memory T cells responding by cytokine release to
HLA-mismatched targets both in direct assays and after 8 days of culturewith allogeneic stimulator cells. Epstein-
Barr virus–specific andcytomegalovirus-specificTcells, tested against a panel of 30Tcell antigen-presenting cells
with a broad coverage of the most prominent HLA types, displayed specificity for certain mismatched HLA al-
leles. Sequencing of the T cell receptor b chain demonstrated a clonotypic identity of cells that responded to
both viral and allogeneic stimulation. These findings showconclusively that alloresponses in humans are not con-
fined to the na€ıve T cell subset, and that memory viral antigen–specific T cells can cross-react with specific mis-
matched HLA–peptide complexes not presenting with cytomegalovirus or Epstein-Barr virus peptides.
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Transplantation of donor hematopoietic cells or
solid organs into a partially HLA-matched recipient
activates CD41 and CD81T cells recognizing alloge-
neic tissues. The high frequency of such alloresponses,
on the order of 0.1%-10%of all T cells [1], has puzzled
investigators. This T cell alloresponse has been pro-
posed to represent either major histocompatibility
complex (MHC)- [2] or peptide-focused [3] recogni-HematologyBranch; 2FlowCytometryCore Facility,Na-
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6/j.bbmt.2010.12.711tion by the T cell receptor (TCR). The consensus is
that such alloreactivity is both MHC-restricted and
peptide-specific, with T cells recognizing either a
peptide in the nonself MHC [4-9] or, alternatively,
a nonself MHC–derived peptide presented and
recognized in the context of self MHC [10-13].
Allloreactivity can be identified in murine and hu-
man T cells directly ex vivo. In murine models, na€ıve,
but not memory, T cells display alloreactivity in vivo
and in vitro [14-17], although recent data in animal
models of graft-versus-host disease (GVHD) suggest
that the memory pool can exert nonself MHC reactiv-
ity as well [18,19]. Based on the findings from murine
T cell allostimulation, where na€ıve T cells produce
tumor necrosis factor (TNF)-a but not interferon
(IFN)-g, it was assumed that any TNF-a produced
by human T cells stimulated ex vivo with HLA-
mismatched targets originated from na€ıve T cells
[20]. However, evidence using cloned T cells suggests
that virus-specific T cells can recognize nonself pep-
tide MHC (pMHC) [21-28]. Because the human T
cell memory pool is largely dominated by reactivities
against common DNA viruses, such as Epstein-Barr
virus (EBV), cytomegalovirus (CMV), herpes simplex
Biol Blood Marrow Transplant 17:800-809, 2011 801Alloreactivity by Na€ıve and Memory T Cellsvirus, and varicella-zoster virus [29-32], the possibility
of frequent cross-reactivity of antigen-experienced T
cells with foreign pMHC is high despite the relative
rarity of individual cross-reactivities.
The distinction between na€ıve and memory T cell
alloreactivity is important in allogeneic hematopoietic
stem cell transplantation (HSCT). Although umbilical
cord blood (UCB) for HSCT contains .99% na€ıve T
cells, which should be capable of strong alloreactivity,
it confers less GVHD than transplants from similarly
mismatched adult sources of bone marrow or periph-
eral blood, conversely suggesting a role for memory
T cells in alloresponses causing GVHD. Indeed, clin-
ical observations in HSCT indicate an association be-
tween DNA virus reactivity and GVHD [33,34].
In the present study, we evaluated the ability of
both na€ıve and antigen-experienced CD4 and CD8 T
cell subsets to recognize and respond to MHC-
mismatched antigen-presenting cells (APCs). Our
findings indicate that both memory and na€ıve T cells
recognize allogeneic targets.MATERIALS AND METHODS
Samples
UCB cells for this research were provided by the
New York Blood Center. Peripheral blood cells were
collected from hematopoietic stem cell transplant do-
nors and from healthy paid volunteers under National
Heart, Lung, and Blood Institute Institutional Review
Board–approved protocols. Informed consent was
obtained in accordance with the Declaration of Hel-
sinki. UCB and adult peripheral blood mononuclear
cells (PBMCs) were isolated using Ficoll-Hypaque
density-gradient centrifugation and cryopreserved in
liquid nitrogen using standard procedures. PBMCs
were thawed and rested overnight at 37C and 5%
CO2 in complete medium (IMDM; Cambrex,
Walkersville, MD) supplemented with 10% heat-
inactivated human AB serum (Gemini Bio-Products,
Woodland, CA), 2 mM L-glutamine, 100 U/mL pen-
icillin, and 100 mg/mL streptomycin (Invitrogen,
Carlsbad, CA) with 50 U/mL of DNase I (Roche,
Indianapolis, IN) before functional assays.Reagents for Flow Cytometry
The following fluorochrome-conjugated mono-
clonal antibodies (mAbs) were purchased from com-
mercial vendors: (1) aCD3 cyanin-7-allophycocyanin
(Cy7APC), aCCR7 biotin, aCD45RA allophycocya-
nin (APC), aCD45RO APC, aCCR5 phycoerytherin
(PE), aCD3 Cy7PE, aCD4 peridinin chlorophyll pro-
tein, aCD4 APC, aCD137 PE, aCD137 biotin,
aCD38 Cy5PE, aCD69 fluorescein isothiocyanate
(FITC), interleukin (IL)-2 FITC, and APC- or Alexa647–conjugated IFN-g (BD Biosciences, San Diego,
CA); (2) aCD4 Cy5.5PE, aCD8 Alexa 750APC,
aCD14 Pacific blue, aCD19 Pacific blue, aCD57
FITC, aTNFa PE, and aIL-2 APC (Invitrogen, Bur-
lingame, CA); (3) aCD27 Cy5PE and aCD45RO PE
(Beckman Coulter, Miami, FL); and (4) aCD4
Cy5.5- peridinin chlorophyll protein (Biolegend, San
Diego, CA). For some experiments, mAbs were conju-
gated in-house; aCD8 and aCD45RA (BD Biosci-
ences) were conjugated to Quantum Dot 585 and
705 (Invitrogen), respectively, and aCD107a was con-
jugated to Alexa 594. Streptavidin PE (BD Biosci-
ences) was used to identify biotinylated mAb-labeled
cells. The fixable violet amine reactive dye (ViViD;
Invitrogen/Molecular Probes, Eugene, OR) or Via-
Probe (7AAD; BD Biosciences) was used to eliminate
dead cells from the analysis [35]. For intracellular
cytokine detection (ICD)–mixed lymphocyte reaction
experiments, cells were labeled with the green fluores-
cent dye carboxyfluorescein diacetate, succinimidyl
ester (CFSE; Invitrogen) [36]. Magnetic beads coated
with mAb toward CD27, CD45RO, CD45RA,
CD57, and CD62L were obtained fromMiltenyi (Ber-
gisch Gladbach, Germany).
Isolation and Expansion of Antigen-Specific
T Cells
PBMCs were stimulated overnight in complete
medium with irradiated (75 Gy) autologous EBV-
transformed lymphoblastoid cell lines (EBV-LCL) or
a custom-synthesized CMV pp65 peptide library as
described previously [37]. Controls were unstimulated
PBMCs. On the next day, the cells were stained with
aCD14 and aCD19 Pacific blue, aCD69 FITC, and
either aCD137 PE or aCD137 biotin, followed by
streptavidin PE, washed, and resuspended in sterile
FACS buffer (phosphate-buffered saline supple-
mented with 2% fetal calf serum and 0.05% sodium
azide; Sigma-Aldrich, St Louis, MO), to which
7AAD was added. Live (7AAD2) CD142CD192 lym-
phocytes brightly expressing CD69 and CD137 were
sorted and further expanded by restimulation with
the same antigen in complete medium supplemented
with 100 IU of recombinant human IL-2 (Tecin;
Roche). After 4 weeks, the T cells were tested for reac-
tivity by ICD with a panel of HLA-disparate PBMCs
or activated T cells (T-APCs) as APCs [37] (Table 1).
Isolation of T Cell Subsets
PBMCs were labeled with magnetic bead-coupled
mAbs (Miltenyi) specific for CD27, CD45RO,
CD45RA, CD57, and CD62L in combinations of
CD57 plus CD45RO, CD57 plus CD45RA, CD57
plus CD62L, and CD27 plus CD45RO to obtain
na€ıve, central memory, effector memory, and effector
T cells, respectively. These fractions were applied to
Table 1. High-Resolution HLATyping of Responder and Stimulator Cells Used in This Study
Subject
HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1 HLA-DRBn
Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2 Allele 1 Allele 2
1 02* 03* 07* 44* 0501 0702 1501 06* 5*00
2 0201 0702 62 1 7 1501 1402 0602 0301 52
3 2601 6801 3503 3901 0401 120301 14* 16* 05* 3*02 5*02
4 240201 240301 380101 5001 0602 1203 1101 1502 0301 0601 3*0202 5*0102
5 2 3 44 51 0401 1101 0301 52 53
6 1 0201 35 62 3V 1001 14* 0501 05* 52 53
7 0206 24 35 3906 0404 1406 0301 0302 52 53
8 020101 110101 3501 4001 0304 0401 0101 1302 0501 06* 3*0301
9 01 25 18 57 06 07 15 0201 06 53
10 24* 29* 1517 44* 07* 16* 0701 1201 3*00 4*01
11 020101 260101 130201 570101 0602 0701 07* 0201 0303 4*01
12 2 28 7 8 7 0301 0701 0201 0303 52 53
13 02* 3001 13* 44* 05* 06* 0101 0301 0201 0501 3*0101
14 01 24 15 44 0401 0801 0302 04 53
15 0101 68* 08* 27* 0202 0701 0301 1101 02* 03* 3*01 3*02
16 0201 3101 51* 0101 0402 03* 0501 4*01
17 2501 6601 07* 41* 0801 1303 0301 04* 52
18 0201 0203 13* 38* 03* 07* 1202 1602 03* 05* 3*00 5*00
19 0201 0203 13* 38* 03* 07* 1202 1602 03* 05* 3*00 5*00
20 03* 30* 42* 57* 0701 1701 0302 1302 0402 0502 3*0101 3*0301
21 030101 110101 3503 510101 040101 0407 1104 0301 0302 4*01 3*0202
22 2401 3303 3801 5001 0602 1203 1401 05* 3*02
23 0201 11 35 58 3 13 1 2
24 240201 290201 3901 4403 120301 160101 0701 1501 0201 0602 4*01
25 29* 32* 35* 44* 04* 16* 0103 0701 0202 0301 4*0101
26 0211 3201 0101 07* 0501 0303 53
27 3002 68* 18* 3905 05* 07* 0301 0802 3*00
28 2301 2403 4901 1501 1501 06*
29 26* 6901 35* 38* 12* 03* 13* 02* 06*
30 11 33 51 52 01 16 05*
31 0205 6601 44* 50* 14* 1501 05* 06* 52
32 010101 6802 080101 140201 0701 0802 03* 13* 02* 0301 3*01 3*01
33 03* 30* 42* 57* 0701 1701 0302 1302 0402 0502 3*0101 3*0301
34 020101 6802 150101 570101 030301 0602 0701 0303 4*01
*Stimulators 18 and 19 and stimulators 20 and 33 are HLA-identical siblings.
802 Biol Blood Marrow Transplant 17:800-809, 2011J. J. Melenhorst et al.an LS column (Miltenyi Biotec), and the unbound (ie,
unlabeled) cells were collected, washed, and cultured
for 8 days with irradiated (50 Gy) HLA-mismatched
targets. The purity of the fractions exceeded 90%.ICD
Donor PBMC and T cell subsets were first primed
by stimulation for 8 days with irradiated HLA-
mismatched PBMCs in complete medium and 5%
CO2 at 37
C. Cells were then labeled with CFSE
and restimulated with the same target cells or the
autologous control for 6 hours in the presence of bre-
feldin A, monensin, and aCD28 and aCD49d (BD
Biosciences). The cells were washed, stained with
ViViD and cell surface mAb, and fixed and permeabi-
lized using the BD Cytofix/Cytoperm Fixation and
Permeabilization Kit following the manufacturer’s in-
structions. The cells were stained with anticytokine
mAb, washed twice with Cytoperm buffer, fixed for
10 minutes at room temperature with 4% formalde-
hyde (Tousimis, Rockville, MD), washed once with
FACS buffer, and then resuspended in FACS buffer
for acquisition. Virus antigen-specific T cells weresimilarly examined for alloreactivity by ICD using
a panel of 30 T-APCs (Table 1). For the direct ex
vivo assessment of allo-HLA reactivity of CD41 and
CD81 T cells, the responder cells were labeled with
CFSE and stimulated for 6 hours at a 1:1 ratio with
(unlabeled) stimulator cells as described earlier.Flow Cytometry
Stained cells were acquired on either a (modified)
LSR II or a Canto II flow cytometer (BD Biosciences).
A minimum of 2  105 events was collected for each
condition. Compensation and data analysis were per-
formed as described previously [35]. Forward scatter-
area versus forward scatter-height properties were
used to exclude cell aggregates; live T cells were sepa-
rated from dead cells, monocytes, and B cells using
a ViViD/CD14/CD19 (dump channel)-versus-CD3
bivariate plot. Lymphocytes were identified in a for-
ward scatter-area versus side scatter-area plot, and re-
sponder cells were identified in the CFSEhi fraction
after restimulation of CFSE-labeled primed allospe-
cific or virus antigen–specific T cells in an ICD
Figure 1. UCBCD41 andCD81 T cells contain a large alloreactive T cell population. A, Gating strategy. Live T cells were identified in a bivariate plot of
CD14/CD19/ViViD versus CD3, and single cells were identified in a forward scatter-area versus forward scatter-height plot. Single intact lymphocytes
were gated in a forward scatter-area versus side scatter-area plot, and CD41 andCD81T cells were identified in the next plot. B, Reactivity of CD41 and
CD81 T cells in 1 of 5 umbilical cord blood mononuclear cells. Responding T cells were identified as CD31 T cells that had serially diluted CFSE and
acquired CD38 expression. Note the lack of response in unstimulated cells and the reactivity of T cells with the positive control staphylococcus entero-
toxin B (SEB). C, Summary of the reactivity of UCB T cells with allogeneic PBMCs. In this box-and-whiskers plot, the horizontal bar represents the
median, the borders are the 25th (lower) and 75th percentiles, and the whiskers are the minimum and maximum values.
Biol Blood Marrow Transplant 17:800-809, 2011 803Alloreactivity by Na€ıve and Memory T Cellsexperiment. Gating was standardized within individual
samples to generate a fully comparative dataset.TCR Sequencing
Virus antigen–specific T cells were restimulated
with the cognate antigen and with T-APCs to which
they displayed reactivity, and then electronically sorted
on a modified BD Biosciences Aria sorter based on
ICD. Sorted cells were collected in a dry collection
tube, and genomic DNA was extracted as described
previously [38]. TCR-Vb sequences were amplified,
cloned, and sequenced as described previously [36,38],
and the composition of the third complementarity-
determining regionwas analyzed using the international
Immunogenetics Information System (http://imgt.
cines.fr/).Statistics
GraphPad Prism v4 (GraphPad, La Jolla, CA) was
used to determine the difference in the magnitude of
the response of alloantigen-primed donor T cells to-
ward PBMCs or T-APCs in the second stimulation
using Wilcoxon’s two-tailed signed-rank test.RESULTS
UCB T Cells Respond to HLA-Disparate
Target Cells
We first tested the alloreactive potential of na€ıve
T cells by stimulatingUCBT cells, which are predom-
inantly phenotypically na€ıve [39], with allogeneic stim-
ulator cells and determining the fraction that had
proliferated and acquired expression of the activation
marker CD38 by day 8. In 5 UCB samples, a median
of 79% of CD41 T cells and 86% of CD81 T cells
were CFSEdimCD381 by day 8 (Figure 1), confirming
that na€ıve T cells respond to HLA-disparate target
cells.Both Na€ıve and Memory T Cell Subsets Contain
Alloreactive Precursor Cells
Next, we separated adult PBMCs into various func-
tional subsets by immunomagnetic depletion and stim-
ulation with a pool of irradiated allogeneic PBMCs. In
our approach,Tcell subsetswere purified free of bound
antibody by negative immunomagnetic selection, and
T cell subsets were identified using well-established
marker combinations [40]. Thus, na€ıve T cells were
Figure 2. Adult donor memory T cell subsets respond to allogeneic target cells (PBMCs and T-APCs). Unfractionated PBMCs and purified na€ıve (N),
central memory (CM), effector memory (EM), and effector (E) T cell subsets were primed for 8 days with irradiated allogeneic PBMCs and then restimu-
lated with the original PBMCs for 6 hours to assess cytokine (IL-2/IFN-g and/or TNF-a) production by the alloantigen-primed T cells. A, Reactivity of the
primed donor CD41 and CD81 T cell fractions with allogeneic PBMCs showing allo-pMHC reactivity by all subfractions. Shown are the background-
subtracted average and standard error of the mean (SEM) in each CD41 (left) and CD81 (right) T cell subset. B, Reactivity of the same primed donor
T cells with allogeneic T-APCs demonstrating essentially the same reactivity pattern. Again, the average and SEM in each CD41 (left) and CD81 (right)
T cell subset are shown. None of the donors had phenotypically effector CD41 T cells.
804 Biol Blood Marrow Transplant 17:800-809, 2011J. J. Melenhorst et al.defined as CD45RA1CD271 and lacking CD57 and
CD45RO; central memory T cells were CD45RO1
CD271, lackingCD45RAandCD57; effectormemory
T cells wereCD45RO1CD271/2, lackingCD62L and
CD57; and effector T cells were CD272CD45RO2
CD45RA1CD571. Consequently, na€ıve T cells were
obtained by depleting cells expressing CD57 and
CD45RO, central memory T cells were obtained by
depleting cells expressing CD45RA and CD57, effec-
tormemoryT cells were obtained by depleting cells ex-
pressing CD62L and CD57, and effector T cells were
obtained by depleting cells expressing CD27 and
CD45RO.
T cells can proliferate in response to common g
chain signaling cytokine stimulation alone [41]. Such
cytokines, including IL-2, are abundantly produced
in a mixed pool of allogeneic PBMCs and could con-
tribute to a TCR-independent T cell proliferation in
the mixed lymphocyte reactions. Thus, in the next
set of experiments, we first primed PBMC and T cell
subsets from 3 donors with HLA-mismatched targets
for 8 days, followed by restimulation with the original
donor PBMCs, and measured antigen response based
on the flow cytometric detection of cytokine (IL-2
and/or TNF-a) production (via ICD) in response to
secondary stimulation. Unstimulated allo-HLA–
primed T cells served as a negative control. In all 3 in-
dividuals (Figure 2A), na€ıve, central, effector memory,
and in some cases effector T cells were primed and re-
sponsive to restimulation with allogeneic target cells in
the secondary 6-hour stimulation.
To exclude the possibility that the memory T cells
were merely responsive to EBV or CMV viral antigens
present in PBMCs, we repeated the same experiment
using activated T-APCs, which do not present these
viral antigens. The pattern was largely the same, except
that the magnitude of the response to restimulation
with T-APCs was significantly greater than that with
PBMCs (P ..05, Wilcoxon’s two-tailed signed-rank
test) (Figure 2B), probably because T-APCs express
high levels of costimulatory molecules plus HLA classII [37,42]. Collectively, these results show that both
na€ıve and memory T cells contribute to the
alloresponse, suggesting that although it removes
undesired self-reactivity from the T cell repertoire,
negative thymic selection does not prevent responses
to antigens presented by nonself MHC.
Both Na€ıve and Memory T Cells Recognize
HLA-Disparate Targets Directly Ex Vivo
Because memory T cells were found to recognize
unrelated pMHC complexes, they are likely to exert
their effector function with fast kinetics and should
be detectable in a short-term stimulation-based assay
using a standard overnight ICD procedure. We first
stimulated PBMCs from 6 responders individually
overnight with 5 HLA-mismatched and one autolo-
gous control PBMC samples in the presence of cyto-
kine secretion inhibitors, and then stained them for
IL-2, IFN-g, and TNF-a. Five of 6 CD41T cell frac-
tions and 2 of 6 CD81 T cell fractions demonstrated
reactivity with HLA-mismatched targets (Figure 3A).
We next assessed the alloreactivity of na€ıve, memory,
and effector CD41 and CD81 T cells. T cells readily
responded to the HLA-mismatched target cell stimu-
lation by producing cytokines (Figure 3B), accounting
for up to 2.35% of CD81 T cells and 0.23% of CD41
T cells. Direct alloreactivity, predominantly by na€ıve
(CD271CD45RO2CD572) and end-stage effector
(CD272CD45RO2CD571) T cells, was demon-
strated in the CD41 and CD81T cell populations, re-
spectively (Figure 3B). These findings indicate that
both na€ıve and effector T cells can respond with fast
kinetics to HLA-disparate target cells.
Virus Antigen–Specific CD41 and CD81 T Cells
Recognize Structurally Disparate Peptide–HLA
Complexes
To extend these observations to T cells with
known specificity, we stimulated donor T cells for up
to 24 hours with either autologous EBV-LCL or
Figure 3. Alloreactive T cell precursors are readily identifiable in both
na€ıve and memory T cells directly ex vivo. A, Frequencies of CD41 (top)
and CD81 T cells from 6 donors (denoted by numbers on the x-axis
corresponding to subject numbers listed in Table 1) responding with
HLA-mismatched target cells. The frequencies displayed are background-
subtracted, that is, after correction for cytokine production in the absence
of allogeneic stimulator cells. Responder CD81 T cells were identified as
cells producing TNF-a and/or IFN-g, and responder CD41 T cells as cells
producing TNF-a and/or IL-2. B, A representative example of one such
analysis demonstrating direct ex vivo cytokine production. Shown is the
phenotype of CD41 and CD81 T cells from donor 11 as a density plot,
with the phenotype of alloreacting T cells overlad in yellow. The figure
shows that alloresponding CD4 T cells lack CD57 expression, and that
the bulk of the responder cells express CD27 but lack CD45RO expres-
sion, indicative of their na€ıve nature. However, a smaller, but sizeable,
fraction also expresses CD45RO, indicating that some CD41 T cells re-
sponding to nonself MHC are contained in the memory (CD271
CD45RO1) pool. On the other hand, the majority of the alloreactive
CD81 T cells express CD57 but not CD27 or CD45RO, indicating that
most alloreactive T cells originate from the end-stage effector pool.
Biol Blood Marrow Transplant 17:800-809, 2011 805Alloreactivity by Na€ıve and Memory T Cellsa pp65 peptide library known to elicit both CD41 and
CD81 T cell responses [37], and then sorted and ex-
panded activated (CD691CD1371) cells for 4 weeks.
We then tested these antigen-specific T cell lines
against a panel of T-APCs expressing the most com-
mon HLA class I and II molecules (Table 1) in an
ICD experiment. The virus antigen–specific CD41
and CD81 T cells displayed specificity for certain re-
stricted target cells, recognizing between 1 and 4
APCs (Figures 4A, S1, and S2). The CMV pp65-
specific CD41 T cells of donor 19 cross-reacted with
targets 20 and 33 (HLA-identical siblings; Figure 4A,
middle panel)). Although stimulators 20 and 33 were
genotypically HLA identical, it is notable that the
alloresponse to APC 33 was 3-fold greater than the
alloresponse to the HLA-identical sibling, suggesting
differences in the self-peptides presented by the 2
individuals.
Identical T Cell Clones Respond to DNAVirus
and Allogeneic pMHC Complexes
To demonstrate that the same T cell clones can re-
spond to both viral and allogeneic pMHC stimulation,
we electronically sorted CD41 and CD81T cells from
the EBV- and CMV-responsive T cell lines described
earlier, based on the intracellular detection of both
TNF-a and IFN-g after stimulation with cognate
(viral) antigen and with an allogeneic T-APC to which
they also responded. Figure 4B shows the response of
two such T cell lines to cognate antigen (pp65 or EBV)
and to allogeneic targets in the CD4 and/or CD8
T cell subsets. To restrict the study to pure viral-
specific T cells, we selected only T cells producing
both TNF-a and IFN-g, because no unstimulated cul-
tured T cells were double positive for these cytokines.
(Figure 4B). Alloresponding CD41 T cells from
a third, anti–EBV-LCLT cell line were selected based
on the expression of TNF-a and/or IFN-g, because
this gave the greatest difference with unstimulated
cells (Figure S3). Sequencing the TCR-b chains in
these samples using our well-established methodology
[38,43] identified identical sequences in viral- and
alloantigen-stimulated cells (Figures 4C and S3),
providing strong evidence of the cross-reactivity of
virus-specific CD41 and CD81 T cells with unrelated
antigens.DISCUSSION
It is well accepted that na€ıve T cells canmount a re-
sponse to any new antigen, whether pathogen-derived
or an allogeneic pMHC complex; however, the contri-
bution of memory cells to allo-HLA reactivity is less
well defined. Numerous previous studies have demon-
strated the alloreactivity of virus antigen-specific
CD41 [23,26-28,44] and CD81 [21-25,44] T cell
Figure 4. Virus-specific CD41 and CD81 T cells recognize allogeneic pMHC. A, CD41 and CD81 T cells from donors 15, 19, and 33 responded to
selected T-APCs with production of IL-2/IFN-g and TNF-a. B, EBV and CMV pp65-specific T cells from donors 15 and 19 were sorted based on the
expression of both TNF-alpha and IFN-gamma upon stimulation with cognate antigen or allogeneic target. The same T cell clone recognized both cog-
nate antigens presented in self-MHC and allogeneic pMHC. Selected and expanded T cells were stimulated with cognate antigen or allogeneic T-APCs,
stained for surface markers and cytokines, and sorted based on cytokine production. The TCR sequences were amplified in 3 separate polymerase chain
reaction (PCR) tubes, each containing the full set of Vb PCR primers but a different set of Jb (BJ) primers. Tube A contained primers specific for TCRBJ
1.1–1.6; tube B contained primers specific for TCRBJ 2.1, 2.3, 2.4, and 2.5; and tube C contained primers specific for TCRBJ 2.2, 2.6, and 2.7. Given that
we examined the TCR repertoire in 3 separate PCR reactions, we indicate clonal dominance per tube (A, B, and C).We obtained a total of 224 in-frame
TCR sequences in this experiment, including 40 and 66 sequences for donor 15’s CD81 T cell response against the cognate and alloantigen, respectively,
and 56 and 62 sequences for donor 19’s CD41 T cell response against the cognate and alloantigen, respectively. The clonotype composition in the sorted
fraction shows identical clonotypes in the respective cell lines, indicated in matching colors for identical clonotypes.
806 Biol Blood Marrow Transplant 17:800-809, 2011J. J. Melenhorst et al.clones (reviewed in [45]), but none of those studies ad-
dressed this issue at the population level as we have
done in the present work. Furthermore, depletion of
na€ıveT cells has been proposed as amethod of avoiding
GVHD after allogeneic HSCT [15,46]. We measured
cytokine production at the single-cell level by flow cy-
tometry in allo-MHC‒primed T cells after short-term
(6 hours) restimulation with the same allogeneic
PBMCs and confirmed their alloreactive potential.The functional readout might not accurately reflect
the true number of alloresponding T cells, however.
In these experiments, we chose to analyze TNF-a
and IFN-gamma/IL-2 production after allogeneic or
syngeneic secondary stimulation; it is possible that re-
sponder frequencies might be different when analyzing
other effector functions. Thus, although our results do
not reflect overall allo-HLA responder T cell frequen-
cies, they do show that responder frequencies to
Biol Blood Marrow Transplant 17:800-809, 2011 807Alloreactivity by Na€ıve and Memory T Cellsallo-HLA stimuli are comparable in na€ıve andmemory
T cells.
Previous assays aimed at demonstrating the allor-
eactive potential of T cells ex vivo have assumed that
such reactivity resides exclusively in the na€ıve pool
[14,20].Using ICD,we show that such allo-pMHCre-
activity can be identified in healthy donor T cells ex
vivo. Importantly, however, by combining such assays
with the phenotypic identification of na€ıve, memory,
and effector T cell subsets in a polychromatic flow cy-
tometry approach, we have demonstrated conclusively
that na€ıve CD41T cells and effector CD81T cells are
the predominant subsets reacting with pMHC targets.
Because the DNA viruses are latently present in
circulating B cells (eg, EBV [47]) and myeloid cells
(eg, CMV [48]), the analysis of allo-pMHC reactivity
of memory T cells could be confounded by responses
to viral antigens presented by the HLA-disparate stim-
ulators. However, activated T cells, which do not carry
EBV or CMV, also elicited alloresponses, excluding
the possibility that the responses were directed against
these common DNA viruses.
The identification of alloreactivity in the memory
pool raises the question of whether cross-reactivity
of viral antigen–specific CD41 and CD81 T cells
occurred with mismatched virus antigen-free pMHC
complexes. Most previous studies have examined only
a few clones against a limited panel of allogeneic
EBV-LCL [27,28,49] or PBMCs [20] as APCs. We
earlier established that the likelihood of finding allor-
eactivity depended on the complexity of the responder
cell population (Melenhorst et al., unpublished obser-
vations) and on the extent of HLA diversity of the T-
APC panel. Activation marker-selected and expanded
virus-specificT cell lines were analyzed for clonal com-
position on restimulation with the cognate antigen (the
immunodominant antigen fromCMV, pp65, or amore
complex source of antigen, EBV-LCL, which are
known to express approximately 8 EBV-encoded
proteins [50]) and with an allogeneic target.
To refine our selection of pure virus-specific
T cells, we sorted only those T cells that produced
both TNF-a and IFN-g in response to cognate or
alloantigen stimulation, because the proportion of T
cells producing both of these inflammatory cytokines
in the absence of restimulation was negligible, whereas
single-cytokine producers were present in the unsti-
mulated populations. TCR-b sequence analysis of
CD41 and CD81 T cells responding to cognate anti-
gen stimulation showed that the responder popula-
tions were highly oligoclonal, confirming previous
reports [51,52]. The examination of the TCR-b
sequences in the same T cell lines responding to an
allogeneic target identified shared clonotypes with
the cognate antigen-responsive population.
To expand our findings with the clonotype analysis
of virus-specific T cell lines reacting with allogeneicAPCs, we subjected a third, CD41 EBV-LCL–
reactive T cell line to the same procedure. Here, we
also identified a shared clonotype between virus-
responding and alloresponding cells (Figure S3). But
because the background production of cytokines by
this cell line (ie, in the absence of antigen stimulation)
was substantial, we cannot formally prove the dual re-
activity of the clone identified in both reactivities. Col-
lectively, our data do allow us to draw the conclusion
that DNA virus antigen–specific T cells, which can
compose 10% or more of the circulating post-HSCT
T cell population in HSCT recipients [51] and in
elderly donors [32], are commonly reactive with unre-
lated pMHC complexes.
Our findings have clinical relevance. First, the
adoptive transfer of virus-specific T cell lines and
clones to treat reactivating viruses in (partially)
matched recipients [53] may risk sporadic but powerful
alloreactions against the recipients. In the present
study, we used T-APCs and PBMCs as representative
GVHD targets because they were readily available;
however, it is possible that these targets are not as rep-
resentative of GVHD targets as fibroblasts or cells
from GVHD target tissues such as the skin, gastroin-
testinal tract, and the liver. Amir et al. [44] recently
used an EBV-LCL, HLA-transduced erythroleukemic
cell line and phytohemagglutinin blasts to demonstrate
that a large proportion of virus antigen–specific T cell
clones reacted with nonself pMHC complexes. Those
findings should be interpreted with caution, however;
in vitro allo-HLA reactivity of virus-specific T cells
might not directly translate to the alloreactivity in
the form of GVHD, because other factors (eg, target
antigen expression, homing, in vivo expansion) can af-
fect clinical outcome. Indeed, the adoptive transfer of
virus-specific T cell lines in the partial HLA-
disparate setting [53,54] was not found to result in
GVHD [55]. Furthermore, a recent study by the Rid-
dell group [56] suggests that even minor histocompat-
ibility antigen–specific T cells selected for reactivity
with hematopoietic targets (EBV-transformed B cells)
but nonreactivity with patient fibroblasts still exerted
antilung reactivity in the patient, indicating that even
fibroblasts might not express the relevant repertoire
of target antigens of GVHD. Second, as others have
demonstrated, cross-reactivity by viral antigen–
specific TCRs with various nonself pMHC complexes
[24] implies that when targeting an epitope presented
in one particular HLA (eg, WT1RMF presented in
the context of HLA-A*0201), TCRs from multiple
clones should be available for such therapeutic applica-
tions, because, depending on the HLA makeup of the
TCR donor, these complexes might recognize unre-
lated pMHC complexes. The same principles may
apply to any TCR challenged with pMHC complexes
not encountered during thymic selection in the origi-
nal host [57]. Finally, because alloreacting memory
808 Biol Blood Marrow Transplant 17:800-809, 2011J. J. Melenhorst et al.T cells, with their rapid proliferation kinetics, may kill
their target within hours of engagement, they may
contribute to the hyperacute GVHD observed mainly
in partially HLA-matched HSCT recipients [58].
Although end-stage effector T cells are short-lived in
vitro [59], they arise from the memory pool and may
continue to replicate [60].
In conclusion, T cell reactivity with unrelated
pMHC complexes can originate from any postthymic
T cell population. Alloreactivity is common and is
mediated by the same TCR that recognizes viral and
possibly self antigens.ACKNOWLEDGMENTS
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